TD Asset Management Inc. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

TD Asset Management Inc. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 359,389 shares of the biopharmaceutical company’s stock after purchasing an additional 29,322 shares during the period. TD Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $256,004,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Raymond James Trust N.A. increased its holdings in shares of Regeneron Pharmaceuticals by 2.9% during the third quarter. Raymond James Trust N.A. now owns 1,064 shares of the biopharmaceutical company’s stock valued at $1,119,000 after acquiring an additional 30 shares in the last quarter. Great Valley Advisor Group Inc. increased its stake in Regeneron Pharmaceuticals by 5.0% during the 3rd quarter. Great Valley Advisor Group Inc. now owns 442 shares of the biopharmaceutical company’s stock valued at $465,000 after purchasing an additional 21 shares in the last quarter. Cerity Partners LLC raised its holdings in shares of Regeneron Pharmaceuticals by 18.5% in the third quarter. Cerity Partners LLC now owns 15,548 shares of the biopharmaceutical company’s stock worth $16,344,000 after buying an additional 2,423 shares during the last quarter. Kingsview Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 2.6% during the third quarter. Kingsview Wealth Management LLC now owns 860 shares of the biopharmaceutical company’s stock worth $904,000 after buying an additional 22 shares during the period. Finally, Pitcairn Co. grew its holdings in shares of Regeneron Pharmaceuticals by 4.8% during the third quarter. Pitcairn Co. now owns 962 shares of the biopharmaceutical company’s stock valued at $1,011,000 after buying an additional 44 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on REGN. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. TD Cowen lowered their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Finally, Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $661.00 on Tuesday. The business’s 50 day moving average price is $688.31 and its 200-day moving average price is $809.71. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market capitalization of $72.26 billion, a PE ratio of 17.27, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $11.86 earnings per share. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.